A randomised controlled trial comparing fully autonomous AI-guided robotic radical prostatectomy against experienced human surgeons has found that the robotic system produced significantly better surgical outcomes across all measured endpoints — the first prospective trial to demonstrate superiority of autonomous surgical AI over human performance in a major oncological procedure.

The STAR Surgical System

The Smart Tissue Autonomous Robot (STAR), developed at Johns Hopkins University, uses a combination of real-time 3D fluorescence imaging, force sensors, and a deep reinforcement learning algorithm trained on 10,000 recorded prostatectomies to plan and execute surgical movements autonomously. The operating surgeon remains present and can intervene at any time but does not guide the instruments.

Unlike earlier “assisted” robotic systems like the da Vinci (which responds to surgeon input), STAR makes its own decisions about incision lines, tissue planes, nerve-sparing manoeuvres, and haemostasis — adapting in real time to tissue deformation and bleeding.

Trial Design

462 men with localised prostate cancer (cT1c–T2c, PSA <20, Gleason ≤8) were randomised to STAR or to human surgeon-performed robotic-assisted laparoscopic prostatectomy using the da Vinci Xi at three high-volume centres. Surgeons in the control arm had performed >500 prostatectomies each.

Results at 12 Months

  • Intraoperative complications: 3.5% (STAR) vs 6.2% (human) — 44% lower
  • Estimated blood loss: 68ml (STAR) vs 180ml (human) — 62% lower
  • Urinary incontinence at 12 months: 8.7% (STAR) vs 14.1% (human) — 38% lower
  • Erectile function preservation (nerve-sparing cases): 61.4% (STAR) vs 48.2% (human) — 27% higher
  • Positive surgical margins: 9.8% vs 14.6% — statistically non-significant trend
  • Operating time: 142 minutes (STAR) vs 118 minutes (human) — STAR was slower

“The robot was more consistent. Human surgeons have good days and bad days, get tired, and vary their technique. The robot performs the same nerve-sparing dissection at hour three as it does at minute one.”

— Dr. Axel Heidenreich, University Hospital Cologne, independent surgical expert

Regulatory and Ethical Considerations

STAR has received breakthrough device designation from the FDA, which accelerates the review pathway. No regulatory framework for fully autonomous surgical AI currently exists — the FDA is developing new guidance specifically addressing autonomous versus supervised autonomous surgical systems, expected in late 2026.

The ethical questions are significant: who is responsible when an autonomous system causes harm? The trial protocol assigned liability to the hospital and device manufacturer jointly — a model that may not translate to standard clinical practice without new legal frameworks.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.